第32届国际先进脊柱外科技术会议(IMAST)

◆ 会议时间：2025年4月2-5号
◆ 会议地点：英国格拉斯哥

◆ 会议简介：

第32届国际先进脊柱外科技术会议(IMAST)将于2025年4月2-5号在英国格拉斯哥举行，会议由脊柱侧凸研究学会（SRS）主办。IMAST是一个聚集一流脊柱外科医生、创新研究与最先进脊柱外科技术的国际会议。三天的会义，来自世界各地的外科医生将讨论、辩论和演示最新的脊柱外科技术，以帮助彼此改善患者护理。大会议题将聚焦治疗各种脊柱疾病的新技术和先进技术。

脊柱侧凸研究学会（SRS）成立于1966年，是国际公认的世界上最权威的脊柱学会之一，专业致力于促进脊柱畸形领域宣的研究和教育。SRS拥有极其严格的会员资格标准，目前拥有超过1000名来自各地的最优秀的脊柱外科医生、从事脊柱畸形研究与治疗的研究人员、医生助理和矫形师会员，他们在各自专业领域内为提高脊柱畸形患者的诊治水平做出了巨大的贡献。SRS每年举办一次全球会议（年会），总结、汇报、交流、讨论当年脊柱畸形（主要为脊柱侧、后凸畸形）领域诊治及研究的成果以及新进展，进而促进全世界范围内脊柱侧凸诊治水平的不断提高。未经许可禁止复制摘录转载本站任何内容-国际医学会议网（lingyuint.com）

IMAST 2025 – 32nd International Meeting on Advance Spine Techniques

Date: April 2 – 5, 2025
Location: Glasgow, Scotland, UK

Organized by: Scoliosis Research Society

摘要征文投稿：

Key Dates

*dates are subject to change

July 1, 2024	Abstract Submission Opens
October 1, 2024 at 11:59pm EDT (US)	Abstract Submission Closes
December 10, 2024	Abstract Acceptance Notification
January 7, 2025	Abstract Acceptance Deadline

点此提交摘要>>>Submit Abstract>>>

The theme for the 2025 IMAST meeting is “Changing Practice with New Technologies.”

Abstract Categories

Abstracts submitted into the SRS meeting must fit into one of the following categories to be considered for participation:

Adolescent Idiopathic Scoliosis	Degenerative Spinal Conditions
Adult Spinal Deformity	Early Onset Scoliosis
AI & Machine Learning*	Kyphotic Deformities
Basic Science, Biomechanics/Genetics	Neuromuscular and Congenital Scoliosis
Cervical Spine: Deformity, Degenerative	Quality/Safety/Value/Complications
Complex (Spondylolisthesis, Tumor, Trauma, etc.)

Authors can choose optional sub-categories to further classify their topic. More than one sub-category can be selected:

Minimally Invasive	Novel Technique
Motion Preservation	Complications

*New Category for IMAST 2025: AI & Machine Learning

Abstracts eligible for this category will describe utilization of artificial intelligence, machine learning, predictive analytics, or wearable technology in the diagnosis, treatment planning, intraoperative guidance, or postoperative care of operative spine pathology.

Abstract Submission Requirements

Submission Portal & Deadline

Abstracts must be submitted online. Complete instructions for submission can be found in the submission portal. The deadline to submit an abstract is Tuesday, October 1, 2024 at 11:59pm EDT (US). No exceptions will be made.

Abstract Length

Submission length is limited to 2,500 characters.

Characters in the abstract title, body and table/image caption will be counted (including spaces). Characters in the author and institution listing will not be counted. There is a strict limit of one graph, figure or table to each submitted abstract. No exceptions will be made.

Previous Publication or Presentation

Abstracts which have been published in journals, meeting proceedings, or other publications, as well as those presented at meetings prior to the SRS meeting to which authors wish to submit are NOT eligible for submission. Only abstracts that have NOT been previously published or presented are eligible for submission.

Disclosure and Licensing Requirement

The Scoliosis Research Society (SRS) must ensure balance, independence, objectivity, and scientific rigor in all educational activities. Therefore, as a person who is in position to influence or control the content of a CME activity, ALL abstract authors must disclose all financial relationships held in the past 24 months with ineligible companies.* If the financial relationship has occurred in the past 24 months, but has since ended, we still require you to disclose the relationship. Visit this link to disclose: https://owpm1.com/abstracts/IMAST/disclosure
The username is the email associated with your abstract and the password your first name.

*An ineligible company is an entity whose primary business is producing, marketing, selling, re-selling, or distributing health care goods or services consumed by or on patients. For specific examples of ineligible companies visit accme.org/standards.

Product-Specific Language

SRS strongly prefers that pharmaceuticals and proprietary software/databases as well as surgical approaches or specific instrumentation such as “Surgimap, MIMICS, EOS Imaging, ROTEM, , XLIF, DLIF, AxiaLIF, Solera, Vertex, Expedium, Mountaineer, Shilla, VEPTR etc.,” are not used in presentations. These terms should be replaced by a generic term or description of the drug, software/database and/or instrumentation or technique unless the use of the term directly impacts learners’ understanding of the presentation or data. Instrumentation may also be referred to when the device name is a landmark system that is no longer sold (i.e. Harrington, Cotrel-Dubousset, Luque). It is recognized that studies evaluating a device or devices or comparing different devices or techniques may require the use of product or technique names. If a device trade name or industry developed technique using a trademarked name are used in an abstract or presentation, it will be specifically reviewed by the CME Committee for evaluation of any relevant financial relationships. When there is a known relevant financial relationship, expanded verbal disclosure will be necessary at the time of presentation. Furthermore, if a product name is mentioned, the audience should be informed of why it is necessary to give the name.

Please view the SRS Product Translation Glossary for more information.

Abstract Review

All abstracts submitted will be reviewed and graded, in blinded fashion, by the IMAST Committee. One-year follow-up is required for papers submitted to IMAST. Based upon abstract grading, those selected will be assigned to a four-minute oral presentation or three-minute E-Point presentation. Acceptance notification will be sent on December 10, 2024.